“…Like all other therapeutic proteins, monoclonal antibodies (mAb) may undergo structural changes during FT processes which lead to protein aggregation, misfolding/unfolding, loss of biological activity or enhanced immune response in patients ( 5 – 7 ). The aggregation process is generally poorly understood ( 8 ) and may have several causes, such as cryoconcentration ( 9 ), contact with interfaces ( 1 , 10 , 11 ), cold denaturation ( 12 , 13 ), and many others ( 14 – 17 ).…”